
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Justin Iacobucci, Associate Publisher.
T: (978) 567-0601
F: (617) 969-2118
Justin joined Pharmaceutical Executive in November 2006. Justin has extensive experience in all aspects of media business with a heightened focus on strategizing and building integrated electronic media programs. Justin is based in Massachusetts.
Area covered: New England, New Jersey, Mid-Atlantic, Southeast






